Clinical Trial Update: Long Term Treatment With L-DOPS

View source ↗

Summary

Regulatory update announcing marketing approval of L-DOPS (droxidopa) for Dopamine beta-hydroxylase deficiency. This marks the availability of long-term treatme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dopamine Beta-hydroxylase Deficiency

Drugs mentioned

• L-DOPS (droxidopa)

Snippet

Sponsor: Vanderbilt University | Conditions: Dopamine Beta Hydroxylase (DBH) Deficiency | Status: APPROVED_FOR_MARKETING